Sociedad Americana de Hirudoterapia

Prevalence, etiology, and transmission of fibropapillomatosis in Olive Ridley turtles at a mass-nesting colony in the Mexican Pacific

Vector-host study published in PLoS ONE (2026)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Seguridad y control de infeccionesLabastida-Estrada E et al. · PloS one, 2026

Abstract

Fibropapillomatosis (FP) is a widespread disease in sea turtles characterized by the development of internal and external tumors that hinder physiological and general functions. Chelonid alphaherpesvirus 5 (ChAHV5) is recognized as the causative agent and has been studied and characterized worldwide. Here, we evaluated the prevalence and severity of FP in olive ridley females (Lepidochelys olivacea) during the mass-nesting season from July 2022 to January 2023 at Playa Escobilla, Oaxaca, on the Mexican Pacific coast. Using fragments of the capsid protein (UL18) and DNA polymerase (UL30) genes, we assessed the molecular detection of viral DNA in tumors and healthy tissues from FP-affected and apparently healthy females. To explore the potential role of the marine leech Ozobranchus branchiatus as a vector, we also screened leeches collected from both FP-affected and healthy turtles for viral DNA. Additionally, we identified ChAHV5 genetic variants from UL18 and UL30 sequences obtained from turtles and leeches. The estimated FP prevalence was 1.05%. Among the 62 FP-affected females, 82% were classified as mild, 13% as moderate, and 5% as severe. Molecular detection using the UL30 marker achieved a 100% detection rate in FP-affected turtles and 91% in apparently healthy individuals. In contrast, viral DNA was detected in only 6% of the analyzed leeches. Based on UL18, we identified a novel variant exclusive to olive ridley turtles (UL18_haplotype 3), while six UL30 variants were recorded, with UL30_Var01 being the most abundant and widely distributed in the Pacific. The low detection rate of ChAHV5 in leeches does not support their role as vectors. Our findings provide critical evidence of latent viral presence and highlight the need for integrating molecular surveillance in nesting sites to improve our understanding of FP dynamics and its potential impact on sea turtle conservation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsTurtlesFemaleMexicoPrevalenceDNA, ViralAlphaherpesvirinaePapillomaPhylogenyHerpesviridae Infections

Resumen

Large mass-nesting study of olive Ridley turtles assessing fibropapillomatosis prevalence and ChHV5 detection in leeches (Ozobranchus branchiatus) — finds low leech detection rate, weak vector role.

Por qué esto importa para la hirudoterapia

Este estudio evaluó la prevalencia de fibropapilomatosis (FP) y la detección del alfaherpesvirus 5 de quelónidos (ChAHV5) en tortugas golfinas (Lepidochelys olivacea) durante el anidamiento masivo en Playa Escobilla, Oaxaca, México (julio de 2022–enero de 2023). La prevalencia de FP se estimó en 1,05%; se detectó ADN viral en el 100% de las tortugas afectadas por FP y en el 91% de los individuos aparentemente sanos utilizando el marcador UL30, pero solo en el 6% de las sanguijuelas Ozobranchus branchiatus examinadas. Los autores concluyeron que la baja tasa de detección en las sanguijuelas no respalda a las sanguijuelas como vectores del ChAHV5. Este estudio es relevante únicamente para la ecología de enfermedades de tortugas marinas y no guarda conexión con la hirudoterapia medicinal ni con el secretoma terapéutico de la sanguijuela.

Citación

Prevalence, etiology, and transmission of fibropapillomatosis in Olive Ridley turtles at a mass-nesting colony in the Mexican Pacific.

Labastida-Estrada E et al. · PloS one, 2026

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.